Moody's Sees Potential Pfizer/Allergan Deal as Credit-Positive Development (PFE) (AGN)

Moody's Investors Service commented that the potential combination of Pfizer Inc. and Allergan Plc would have credit positive implications for both companies. The companies have confirmed friendly discussions, but no deal has been reached and there is currently no impact to the ratings of either company. Pfizer is rated A1 with a stable outlook and Allergan's rated subsidiaries, including Allergan, Inc., are rated Baa3 with a stable outlook.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• EMA validates Pfizer and Valneva's Lyme disease vaccine application
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'